Company intelligence / Profile preview

Salarius Pharmaceuticals

Houston, Texas, United Statessalariuspharma.com ↗

Ownership: Public · SLRX
Development stage: Phase 1

Overview

Seclidemstat in combination with azacitidine showed a 43% overall response rate among 14 predominantly higher-risk MDS and CMML patients who previously failed or relapsed after hypomethylating agent therapy. Median overall survival was 18.5 months with median event-free survival of 7.2 months. The trial was temporarily placed on partial clinical hold by FDA in July 2024 following a serious adverse event, but the hold was lifted in February 2025[9].

Therapeutic areas: Oncology
Modalities: Small moleculesprotein degraderstargeted protein inhibitors (TPIs)targeted protein degraders (TPDs)
Industry: Biotech

Drug pipeline

2 assets

seclidemstat

Phase 1/2

Indications: Ewing sarcoma, Myelodysplastic syndrome

1 more asset in the full pipeline.

Partnerships

National Pediatric Cancer FoundationCancer Prevention and Research Institute of Texas (CPRIT)MD Anderson Cancer Center

Beyond the preview

Go deeper on Salarius Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Salarius Pharmaceuticals.